Article Text

Download PDFPDF
Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease

Statistics from



Do angiotensin receptor blockers protect against or slow the progression of dementia and Alzheimer's disease?


Participants were 819 491 older adults (98% male; aged ≥65 as of October 2002) with cardiovascular disease. More than 11 500 were taking angiotensin receptor blockers (ARBs), >91 000 were taking the angiotensin-converting enzyme (ACE) inhibitor lisinopril and >696 000 were taking other cardiovascular drugs (which included β blockers and calcium channel antagonists, and excluded ARBs, ACE inhibitors and statins). The study included those without a diagnosis of dementia or Alzheimer's disease at baseline (2001–2002) as well as those with these diagnoses.


Administrative database of the US Veteran Affairs; data collected October 2001 to September 2006.

Prognostic factors:

Use of angiotensin receptor blockers, lisinopril, combinations of these or other cardiovascular medications. Lisinopril was selected as a comparator, as ACE inhibitors are a similar drug class to ARBs and share indications, and lisinopril has the largest group of users of the ACE inhibitors.


Time to incident of Alzheimer's disease or …

View Full Text


  • Sources of funding The Retirement Research Foundation and The Casten Foundation


  • Competing interests None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles